Abel Hall LLC
RXRX icon

Abel Hall LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Abel Hall LLC’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$94.4K Buy
22,856
+9,651
+73% +$32.7K 0.02% 785
2026
Q2 		$48.5K Buy
+13,205
New +$44K 0.01% 897

Other funds holding RXRX

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Sowell Financial Services
Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Values First Advisors
Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return

Abel Hall LLC's RXRX Position: Q3 2026 in Review

Abel Hall LLC increased its Recursion Pharmaceuticals (RXRX) stake by 73% in Q3 2026, buying an estimated $32.7K and bringing the position to 22,856 shares worth $94.4K. The position accounts for 0.02% of the portfolio, ranked #785.

Abel Hall LLC first reported a position in RXRX in Q2 2026 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Abel Hall LLC held 22,856 shares of Recursion Pharmaceuticals worth $94.4K as of Q3 2026.
  • Abel Hall LLC bought 9,651 Recursion Pharmaceuticals shares in Q3 2026, an estimated $32.7K.
  • Recursion Pharmaceuticals made up 0.02% of Abel Hall LLC's portfolio in Q3 2026, its #785 holding.
  • Abel Hall LLC first reported a position in Recursion Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.